Class information for:
Level 1: PROTEASOME INHIBITOR//BORTEZOMIB//PROTEASOME

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
5140 1666 47.3 90%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
204 3       PROTEASOME//UBIQUITIN//UNFOLDED PROTEIN RESPONSE 52492
677 2             PROTEASOME//UBIQUITIN//PROTEASOME INHIBITOR 13186
5140 1                   PROTEASOME INHIBITOR//BORTEZOMIB//PROTEASOME 1666

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 PROTEASOME INHIBITOR authKW 1649799 17% 31% 290
2 BORTEZOMIB authKW 1338082 21% 21% 348
3 PROTEASOME authKW 303705 16% 6% 268
4 CARFILZOMIB authKW 271458 2% 37% 40
5 PROTEASOME INHIBITION authKW 257680 3% 25% 57
6 PS 341 authKW 247754 2% 52% 26
7 SYRBACTIN authKW 164941 1% 100% 9
8 MARIZOMIB authKW 164935 1% 75% 12
9 CEP 18770 authKW 109961 0% 100% 6
10 OPROZOMIB authKW 109961 0% 100% 6

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Oncology 8874 38% 0% 638
2 Chemistry, Medicinal 2505 12% 0% 201
3 Hematology 1648 10% 0% 171
4 Pharmacology & Pharmacy 721 14% 0% 240
5 Biochemistry & Molecular Biology 532 19% 0% 313
6 Cell Biology 418 10% 0% 167
7 Chemistry, Organic 220 7% 0% 114
8 Medicine, Research & Experimental 57 3% 0% 57
9 Immunology 48 5% 0% 76
10 Biophysics 15 2% 0% 38

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 INTEGRATED PROT SCI 54769 2% 9% 33
2 ZENTRUM MED BIOTECHNOL 52172 1% 19% 15
3 LEHRSTUHL BIOCHEM 44010 2% 10% 25
4 BIOMETRY STAT ANAL 41234 0% 75% 3
5 JEROME LIPPER MULTIPLE MYELOMA 38065 1% 9% 24
6 MED STUDY PROGRAM 36654 0% 100% 2
7 VATAN CLIN 36654 0% 100% 2
8 JEROME LIPPER MYELOMA MED ONCOL 35238 0% 38% 5
9 EDUC DRUG DISCOVERY 31570 1% 19% 9
10 FRED WYSZKOWSKI CANC 27336 1% 15% 10

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 MOLECULAR CANCER THERAPEUTICS 6114 2% 1% 37
2 CLINICAL CANCER RESEARCH 3935 3% 0% 57
3 CHEMISTRY & BIOLOGY 1958 1% 1% 17
4 CURRENT CANCER DRUG TARGETS 1545 1% 1% 9
5 INVESTIGATIONAL NEW DRUGS 1383 1% 1% 14
6 JOURNAL OF MEDICINAL CHEMISTRY 1370 2% 0% 41
7 CANCER CHEMOTHERAPY AND PHARMACOLOGY 1282 1% 0% 23
8 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 1157 2% 0% 41
9 CANCER BIOLOGY & THERAPY 1081 1% 0% 13
10 JOURNAL OF ANTIBIOTICS 1067 1% 0% 20

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 PROTEASOME INHIBITOR 1649799 17% 31% 290 Search PROTEASOME+INHIBITOR Search PROTEASOME+INHIBITOR
2 BORTEZOMIB 1338082 21% 21% 348 Search BORTEZOMIB Search BORTEZOMIB
3 PROTEASOME 303705 16% 6% 268 Search PROTEASOME Search PROTEASOME
4 CARFILZOMIB 271458 2% 37% 40 Search CARFILZOMIB Search CARFILZOMIB
5 PROTEASOME INHIBITION 257680 3% 25% 57 Search PROTEASOME+INHIBITION Search PROTEASOME+INHIBITION
6 PS 341 247754 2% 52% 26 Search PS+341 Search PS+341
7 SYRBACTIN 164941 1% 100% 9 Search SYRBACTIN Search SYRBACTIN
8 MARIZOMIB 164935 1% 75% 12 Search MARIZOMIB Search MARIZOMIB
9 CEP 18770 109961 0% 100% 6 Search CEP+18770 Search CEP+18770
10 OPROZOMIB 109961 0% 100% 6 Search OPROZOMIB Search OPROZOMIB

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref. in
cl.		 Shr. of ref. in
cl.		 Citations
1 MICALE, N , SCARBACI, K , TROIANO, V , ETTARI, R , GRASSO, S , ZAPPALA, M , (2014) PEPTIDE-BASED PROTEASOME INHIBITORS IN ANTICANCER DRUG DESIGN.MEDICINAL RESEARCH REVIEWS. VOL. 34. ISSUE 5. P. 1001 -1069 148 75% 6
2 KISSELEV, AF , VAN DER LINDEN, WA , OVERKLEEFT, HS , (2012) PROTEASOME INHIBITORS: AN EXPANDING ARMY ATTACKING A UNIQUE TARGET.CHEMISTRY & BIOLOGY. VOL. 19. ISSUE 1. P. 99 -115 92 65% 186
3 GENIN, E , REBOUD-RAVAUX, M , VIDAL, J , (2010) PROTEASOME INHIBITORS: RECENT ADVANCES AND NEW PERSPECTIVES IN MEDICINAL CHEMISTRY.CURRENT TOPICS IN MEDICINAL CHEMISTRY. VOL. 10. ISSUE 3. P. 232-256 131 64% 63
4 RENTSCH, A , LANDSBERG, D , BRODMANN, T , BULOW, L , GIRBIG, AK , KALESSE, M , (2013) SYNTHESIS AND PHARMACOLOGY OF PROTEASOME INHIBITORS.ANGEWANDTE CHEMIE-INTERNATIONAL EDITION. VOL. 52. ISSUE 21. P. 5450-5488 109 47% 32
5 BECK, P , DUBIELLA, C , GROLL, M , (2012) COVALENT AND NON-COVALENT REVERSIBLE PROTEASOME INHIBITION.BIOLOGICAL CHEMISTRY. VOL. 393. ISSUE 10. P. 1101 -1120 74 70% 26
6 CHEN, D , FREZZA, M , SCHMITT, S , KANWAR, J , DOU, QP , (2011) BORTEZOMIB AS THE FIRST PROTEASOME INHIBITOR ANTICANCER DRUG: CURRENT STATUS AND FUTURE PERSPECTIVES.CURRENT CANCER DRUG TARGETS. VOL. 11. ISSUE 3. P. 239 -253 74 48% 212
7 RUSSO, A , BRONTE, G , FULFARO, F , CICERO, G , ADAMO, V , GEBBIA, N , RIZZO, S , (2010) BORTEZOMIB: A NEW PRO-APOPTOTIC AGENT IN CANCER TREATMENT.CURRENT CANCER DRUG TARGETS. VOL. 10. ISSUE 1. P. 55-67 62 85% 17
8 HUBER, EM , GROLL, M , (2012) INHIBITORS FOR THE IMMUNO- AND CONSTITUTIVE PROTEASOME: CURRENT AND FUTURE TRENDS IN DRUG DEVELOPMENT.ANGEWANDTE CHEMIE-INTERNATIONAL EDITION. VOL. 51. ISSUE 35. P. 8708-8720 72 60% 49
9 GRAWERT, MA , GROLL, M , (2012) EXPLOITING NATURE'S RICH SOURCE OF PROTEASOME INHIBITORS AS STARTING POINTS IN DRUG DEVELOPMENT.CHEMICAL COMMUNICATIONS. VOL. 48. ISSUE 10. P. 1364 -1378 79 59% 21
10 MOMOSE, I , KAWADA, M , (2016) THE THERAPEUTIC POTENTIAL OF MICROBIAL PROTEASOME INHIBITORS.INTERNATIONAL IMMUNOPHARMACOLOGY. VOL. 37. ISSUE . P. 23 -30 66 65% 1

Classes with closest relation at Level 1


Rank Class id link
1 1429 PROTEASOME//MULTICATALYTIC PROTEINASE//IMMUNOPROTEASOME
2 20553 KAITOCEPHALIN//ALPHA SUBSTITUTED SERINE//CONAGENIN
3 30421 NELFINAVIR//SAQUINAVIR NO//BECN1 PTDINS3K COMPLEX
4 35160 TRIPEPTIDYL PEPTIDASE II//TPPII//TRIPEPTIDYL PEPTIDASE
5 337 MULTIPLE MYELOMA//LENALIDOMIDE//BORTEZOMIB
6 25950 SKIN BARRIER NETWORK HUMAN OURCES DEV TEAM BK2//LEWY BODY INCLUSION//3 4 5 TRICAFFEOYLQUINIC ACID
7 36059 UBCH10//UBE2C//UBE2Q1
8 14041 AUTOPHAGY//DESMIN RELATED CARDIOMYOPATHY//CARDIOVASC ALTERNAT MED
9 3837 DEUBIQUITINATING ENZYME//UBIQUITIN//DEUBIQUITINASE
10 17458 MYELOMA BONE DISEASE//MULTIPLE MYELOMA//BONE DISEASE

Go to start page